Asthma is a chronic inflammatory respiratory disease characterized by airway inflammation, airway hyperresponsiveness and reversible airway obstruction. Understanding the mechanisms that underlie the various endotypes of asthma could lead to novel and more personalized therapies for individuals with asthma. Using a tissue inhibitor of metalloproteinases 1 (TIMP-1) knockout murine allergic asthma model, we previously showed that TIMP-1 deficiency results in an asthma phenotype, exhibiting airway hyperreactivity, enhanced eosinophilic inflammation and T helper type 2 cytokine gene and protein expression following sensitization with ovalbumin. In the current study, we compared the expression of Galectins and other key cytokines in a murine allergic asthma model using wild-type and TIMP-1 knockout mice. We also examined the effects of Galectin-3 (Gal-3) inhibition on a non-T helper type 2 cytokine interleukin-17 (IL-17) to evaluate the relationship between Gal-3 and the IL-17 axis in allergic asthma. Our results showed a significant increase in Gal-3, IL-17 and transforming growth factor-b 1 gene expression in lung tissue isolated from an allergic asthma murine model using TIMP-1 knockout. Gal-3 gene and protein expression levels were also significantly higher in lung tissue from an allergic asthma murine model using TIMP-1 knockout. Our data show that Gal-3 may regulate the IL-17 axis and play a pivotal role in the modulation of inflammation during experimental allergic asthma.
Introduction
Asthma is a common respiratory disease, afflicting 10% of the US population, affecting 24 million Americans, [1] [2] [3] and is characterized by airway inflammation. Asthmarelated emergency room visits and hospitalizations lead to annual costs of almost $2 billion in the USA for urgent care for asthma. 4 Although asthma has been traditionally defined as a T helper type 2 (Th2) -driven response associated with increased levels of interleukin-4 (IL-4), IL-13 and IL-5 5 that is responsive to corticosteroid treatment, almost 50% of asthma cases do not appear to have Th2-driven inflammation. 6 It is being recognized that asthma is a multifaceted disease with heterogeneous phenotypes and corresponding mechanistic variants, termed endotypes. 7 A broad division of asthma endotypes separate eosinophilic and non-eosinophilic asthma, including neutrophilic, paucigranulocytic and mixed granulocytic subtypes. 8 Understanding the mechanisms underlying the various endotypes of asthma should lead to novel and more personalized therapies for individuals with asthma.
Several studies have indicated that cell-surfaceexpressed glycans such as the Galectin family play an important role in trafficking, migration and recruitment of leucocytes during inflammation by virtue of their ability to bind to selectins. 10, 11 The Galectin protein family are b-galactoside-binding lectins comprising homologous carbohydrate recognition domains, which function in a variety of biological processes including inflammation and allergic pathologies. Galectins may modulate cell adhesion by inhibiting or enhancing adhesive potential between cells or between cells and the extracellular matrix (ECM). Galectins bind glycoconjugates of the ECM via the carbohydrate recognition domains. The extracellular and intracellular concentrations and surface expression of Galectin-3 (Gal-3) is increased during inflammation. [12] [13] [14] Gal-3 is expressed in many airway cell types including macrophages, eosinophils, neutrophils and mast cells, and is reported to play an important role in neutrophil recruitment and activation. 10, 11, 14 Expression of Gal-3 was observed in both the nucleus and cytoplasm, which is consistent with a variable subcellular location of the protein participating in different processes in separate asthma inflammatory phenotypes based on cellular location. 10 However, the role played by Galectins, specifically Gal-3, in eosinophil and neutrophil recruitment, particularly in the context of allergic airway inflammation, is unknown.
Asthma is a chronic inflammatory respiratory disease associated with both allergic and non-allergic mechanisms, with allergic asthma endotypes associated with Th2 elements, and non-allergic asthma endotypes associated with non-Th2-associated elements, such as Th1, Th17 and neutrophilic inflammation. 15 With 50% of asthma linked to non-Th2 mechanisms associated with a variable response to corticosteroid therapy, intricate integration of animal and human studies is necessary to delineate the molecular phenotypes of this asthma type. 6 We have previously shown that genetic deficiency of TIMP-1 results in an asthma phenotype, exhibiting airway hyperreactivity, enhanced cellular peribronchial (eosinophilic) inflammation, increased Th2 cytokine gene and protein expression and significantly reduced dynamic lung compliance following sensitization with ovalbumin. 15 Increased TIMP-1 levels result in ECM accumulation, whereas loss of TIMP-1 leads to matrix metalloproteinase (MMP) -mediated enhanced matrix proteolysis, hence TIMP-1 levels can modulate ECM turnover. The MMP, MMP-2 and MMP-9 efficiently cleave Gal-3 into two fragments, allowing the carbohydrate domain to bind to glycosylated ligands with higher affinity. The MMPs, however, abrogate the ability of these Gal-3 fragments to re-associate and develop homodimers. 16, 17 As both TIMP-1 and Gal-3 are correlated with ECM turnover, we wanted to examine the levels of Gal-3 in TIMP-1 knockout (KO) and wild-type (WT) mice in both ovalbumin (OVA) sensitized and SHAM groups. We examined the gene expression levels of key members of the Galectin family, specifically Galectin-1 (Gal-1), Gal-3 and Galectin-9 (Gal-9) as well as levels of pro-inflammatory cytokines such as transforming growth factor-b 1 (TGF-b 1 ), IL-1b, interferon-c (IFN-c) and IL-17 with a 2 9 2 factorial experiment examining the effect of OVA-induced allergic asthma versus SHAM interventions on WT and TIMP-1 KO mice. We also examined the effects of Gal-3 inhibition on the key cytokine IL-17 using Gal-3 small interfering RNA (siRNA) transfected lung epithelial cells A549, to evaluate the relationship between Gal-3 and the IL-17 axis in lung epithelial cells.
Our results showed a significant increase in Gal-3, IL-17 and TGF-b 1 gene expression in lung tissue isolated from OVA-sensitized TIMP-1 KO mice compared with WT SHAM mice. Gal-3 gene and protein expression levels were significantly higher in lung tissue from OVAsensitized TIMP-1 KO mice compared with WT OVAsensitized mice or TIMP-1 KO SHAM mice. Our data supports the premise that Gal-3 may play a role in the regulation of the IL-17A axis during experimental allergic asthma.
Material and methods

Materials
Tissue procurement: Lung tissue and serum were obtained from C57BL/6 TIMP-1 KO and WT mice, that were both SHAM and OVA-sensitized as previously described. 15 Collection (Manassas, VA) and are grown as adherent cultures in complete Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, NY), supplemented with 10% (volume/volume) fetal bovine serum (Hyclone, Logan, UT), 100 units/ml penicillin and 100 units/ml streptomycin (Gibco, Grand Island, NY). All cells were maintained in a humidified incubator with 5% CO 2 at 37°.
Cell viability: A549 cells were treated with Gal-3 siRNA (concentrations 10-20 pmol) and the Gal-3 inhibitor (Ac-SDKP) (concentrations 5-10 nmol) in our experiments and we tested the cell viability at those concentrations using both Trypan blue dye exclusion and MTT assay (Vybrantâ MTT Cell Proliferation Assay; Thermo Fisher Scientific, Waltham, MA). Data from both assays showed no significant toxicity and > 95% cell viability in cells treated with Gal-3 siRNA at both 10 and 20 pmol concentrations and Gal-3 inhibitor, Ac-SDKP, at both 5 and 10 nmol concentrations, respectively.
Small-interfering RNA: Gal-3-siRNA (5 0 -GGGAAU-GAUGUUGCCUUCCACUUUA-3 0 ) and control-siRNA (5 0 -UUCUCCGAACGUGUCACGUTT-3 0 ) were produced by Thermo Fisher Scientific. Transient transfection was performed using the Lipofectamine RNAi MAX reagent (Invitrogen) following the manufacturer's protocols. A549 cells (1 9 10 5 cells/ml) were seeded into a six-well plate at 24 hr before transfection. The lyophilized siRNAs were dissolved in diethylpyrocarbonate-treated water according to the manufacturer's instructions and A549 cells were treated with siRNA. Cells were harvested within 48-72 hr post transfection for further experiments.
Methods
RNA extraction: Cytoplasmic RNA was extracted using Trizol reagent (Invitrogen-Life Technologies, Carlsbad, CA) using lung tissue (entire lung) that was stored at À80°in RNAlater (Ambion, Austin, TX). The amount of RNA was quantified using a Nano-Drop ND-1000 spectrophotometer (Nano-Drop Technologies, Wilmington, DE) and isolated RNA was stored at À80°until batch analysis was performed.
Real-time quantitative PCR: Gene expression studies were performed on lung tissue obtained from OVA-sensitized as well as SHAM-treated groups of both TIMP-1 KO and WT mice. Additionally, gene expression studies were performed on lung epithelial cells (A549 cell line) in which the Gal-3 gene expression was silenced using siRNA targeting Gal-3. Cytoplasmic RNA was extracted using Trizol, RNA was reverse transcribed to cDNA and relative abundance of Gal-1, Gal-3, Gal-9, TGF-b 1 , TGFb 3 , IL-1b, IFN-c) and IL-17(A-E) mRNA was quantified using real-time PCR. Gene expression levels were expressed as the Transcript Accumulation Index. Untreated cells were used as controls. Five hundred nanograms of total RNA was used for the reverse transcription reaction (25 ll total volume) with the First-Strand cDNA synthesis kit (GE Healthcare, Piscataway, NJ), according to the manufacturer's instruction. One microlitre of the resultant cDNA from the reverse transcription reaction was employed as the template in PCRs using commercially synthesized, well validated PCR primer sequences obtained from www.realtimeprimers.com. The housekeeping gene, b-actin, was used as an internal control. The final primer concentration used in the PCR was 0Á1 lM. PCR was performed using a quantitative PCR machine (Mx3005P; Stratagene, La Jolla, CA) with the following PCR conditions: 95°for 3 min, followed by 24 cycles of 95°for 40 seconds, 58°for 30 seconds and 72°for 1 min; the final extension was at 72°for 5 min. Gene expression was calculated using the comparative CT method. 18 The threshold cycle (Ct) of each sample was determined, and the relative level of a transcript (2DCt) was calculated by obtaining DCt (test Ct À b-actin Ct) and the Transcript Accumulation Index was calculated as 2 ÀDDCT .
Galectin-3 ELISA: We measured Gal-3 levels in serum obtained from TIMP-1 KO and WT mice in both OVAsensitized and SHAM groups using a commercially available ELISA kit (RayBioâ Mouse Gal-3 ELISA Kit Cat # ELM-Galectin-3 RayBiotech, Inc., Norcross, GA 30092). This assay has excellent specificity for detection of Gal-3 with an assay range of 10-10 000 pg/ml and minimum detectability/sensitivity of 6 pg/ml. No significant crossreactivity between analytes and analogues was observed.
Western blotting analysis: Protein was extracted from lung tissue obtained from the four groups of mice, namely the TIMP-1 KO and WT mice, that were both SHAM-and OVA-sensitized, using the T-PER Tissue Protein Extraction Reagent (Cat #78510; Thermo Fisher Scientific). Protein concentrations were measured using the Nano-Drop ND-1000 spectrophotometer (Nano-Drop Technologies).
Fifty micrograms of protein was loaded on a 10-20% Novex TM electrophoresis gel (Cat # XP00100BOX, TrisGlycine, 10-well mini gel; Thermo Fisher Scientific). Protein separation by gel electrophoresis was followed by electro-blotting and protein transfer onto a PVDF membrane using the iBlot TM system (Original iBlotâ Gel Transfer Device; Thermo Fisher Scientific). Protein blots were blocked with Blocking buffer (3% PBS in 19 PBST) and incubated overnight with the following primary mouse antibodies: anti-Gal-3 antibody (Cat # ab2785; Abcam, Cambridge, MA) (1 : 500) or anti-b-actin (Cat # ab8226; Abcam) (1 : 1000). After an overnight incubation with primary antibodies, blots were washed three times in 19 PBST followed by treatment with anti-mouse alkaline phosphatase-conjugated secondary antibody at a dilution of 1 : 5000 (in 2Á5% bovine serum albumin in PBST buffer) for 1Á5 hr at room temperature. All antibodies were obtained from Abcam. b-Actin expression was used to Statistical analysis: Data are expressed as mean AE SD. Statistical comparisons were made between genotypes using a two-tailed t-test. A P-value of < 0Á05 was considered statistically significant. Analyses were performed using PRISM (GraphPad Software, Inc., San Diego, CA) software.
Results
Expression levels of Galectins and key cytokines in TIMP-1 KO mice in comparison with WT SHAM mice
We examined the expression levels of key Galectins and cytokines that are relevant to allergic asthma using realtime PCR. Comparative analysis was done to examine the gene expression levels of Gal-1, Gal-3, -9, TGF-b 1 , TGFb 3 , IL-1b, IFN-c and IL-17 between OVA-sensitized TIMP-1 KO OVA (Group III) and WT SHAM (Group II) (Fig. 1a) . Our data showed a significant increase in the Gal-3 (130% increase; P < 0Á005), TGF-b 1 (394% increase; P < 0Á004) and IL-17 (56% increase; P < 0Á003) and a decrease in Gal-9 (47% decrease, P < 0Á004) gene expression between the OVA-sensitized TIMP-1 KO group and the WT SHAM controls. Comparative analysis to examine gene expression of Galectins and inflammatory cytokines above were also performed in lung tissue obtained from OVA-sensitized TIMP-1 KO mice versus OVA-sensitized WT mice. Our data (Fig. 1b) showed trends that were similar to those observed between Group II and Group III. Specifically, we observed significant increase in the Gal-3 (95% increase; P < 0Á01), TGF-b 1 (750% increase; P < 0Á00001) and IL-17 (41% increase; P < 0Á05) and a decrease in Gal-9 (42% decrease, P < 0Á05) gene expression between the OVA-sensitized TIMP-1 KO mice and the OVA-sensitized WT mice.
Serum Gal-3 levels in the four study groups
We evaluated the Gal-3 protein levels via ELISA in the serum obtained from mice in the following four study groups: WT OVA (Group I), WT SHAM (Group II), TIMP-1 KO OVA (Group III), and TIMP-1 KO SHAM (Group IV). Our results (Fig. 2) show a significant increase in Gal-3 levels in OVA-sensitized animals both in the WT OVA and TIMP-1 KO OVA mice compared with the SHAM groups. However, on comparisons between OVA-sensitized TIMP-1 KO mice and OVA-sensitized WT mice, the Gal-3 levels were significantly higher in the OVA-sensitized TIMP-1 KO mice (45Á68 AE 12Á52 versus 36Á76 AE 4Á93 pg/ml; P < 0Á05). No significant differences in the Gal-3 levels were observed between the WT SHAM and the TIMP-1 KO SHAM mice (7Á15 AE 5Á56 versus 8Á31 AE 1Á1 pg/ml; P = NS). Comparison of Gal-3 levels between WT SHAM and the TIMP-1 KO OVA mice (7Á15 AE 5Á56 versus 45Á68 AE 12Á52 pg/ml; P < 0Á001) showed a significant increase in Gal-3 levels in the TIMP-1 KO OVA mice. Galectin-3 gene and protein expression in the four study groups
We evaluated the Gal-3 gene and protein expression in lung tissue obtained from mice in the four study groups: WT OVA (Group I), WT SHAM (Group II), TIMP-1 KO OVA (Group III) and TIMP-1 KO SHAM (Group IV). Gal-3 gene expression levels were quantified using real time quantitative PCR. Our results (Fig. 3a) show an increase in Gal-3 expression levels in the WT OVA (0Á88 AE 0Á04; P = NS) and TIMP-1 KO OVA (0Á98 AE 0Á03; P < 0Á05) mice compared with the WT SHAM (0Á78 AE 0Á005) mice. No significant difference in Gal-3 gene expression was observed on comparison between OVA-sensitized TIMP-1 KO (0Á98 AE 0Á03; P < 0Á05) mice and OVA-sensitized SHAM (0Á91 AE 0Á02; P = NS) mice. Figure 3 (b) shows representative data of Gal-3 protein expression levels measured by Western blot analysis in the four study groups. Our cumulative Gal-3 protein expression results (Fig. 3c) show significantly higher Gal-3 levels in both the OVA-sensitized TIMP-1 KO and OVA-sensitized SHAM mice compared with respective non-OVA-sensitized controls, indicating that OVA sensitization significantly increases Gal-3 protein Galectin-3 (26 000) β-Actin (42 000) expression. Comparison of Gal-3 protein levels between WT SHAM versus the TIMP-1 KO OVA mice showed a significant increase (72%; P < 0Á0001) in Gal-3 protein levels in the TIMP-1 KO OVA mice.
Galectin-3 gene silencing modulates levels of IL-17 in lung epithelial A549 cells
We observed a significant increase in IL-17 levels in the OVA-sensitized TIMP-1 KO mice. There is evidence that IL-17 attenuates allergic responses in asthma, and is important for neutrophil recruitment. [19] [20] [21] Interleukin-17 has been detected in bronchial biopsies, bronchoalveolar lavage fluid and sputum from asthma patients. 11, [22] [23] [24] [25] [26] [27] [28] We posit that Gal-3 plays a key role in asthma immunopathogenesis by modulating the inflammatory response via the steroid-insensitive Th17 pathway. To investigate the role of Gal-3 in the immunomodulatory response in lung epithelial cells, we transfected the lung epithelial A549 cells using Gal-3 siRNA and 48 hr post transfection, evaluated the Gal-3 gene expression levels (Fig. 4) as well as the gene expression levels of several members of the IL-17 family, specifically IL-17A-E (Fig. 6) . A known Gal-3 inhibitor N-acetyl-seryl-aspartyllysyl-proline (Ac-SDKP), 29 a naturally occurring tetrapeptide was used as a control, in addition to an siRNA with scrambled sequences as a transfection control. Our results (Fig. 4) showed a 61% (P < 0Á01) and 65% (P < 0Á001) decrease in Gal-3 gene expression on treatment with 10 and 20 pmol of Gal-3 siRNA, respectively. Further, treatment of A549 cells with the Gal-3 inhibitor peptide Ac-SDKP resulted in a 35% (P < 0Á05) and 78% (P < 0Á001) decrease in Gal-3 gene expression at concentrations of 5 and 10 nmol of the inhibitor, respectively.
We evaluated the effect of Gal-3 inhibition on the gene expression of some key pro-inflammatory cytokines namely, monocyte chemoattractant protein (MCP-1), IL-8 and IL-6 by treating the A549 cells with 10 nmol Gal-3 inhibitor peptide Ac-SDKP. Statistical comparisons were performed between Ac-SDKP-treated A549 cells and untreated A549 cells used as controls. Our results (Fig. 5) showed that treatment with Gal-3 inhibitor peptide (10 nmol) resulted in a 45% decrease (P < 0Á05) in MCP-1 gene expression; a 65% increase (P < 0Á01) in IL-8 gene expression and a 16% increase (P = NS) in IL-6 gene expression levels compared with the respective untreated controls (Fig. 5) .
Galectin-3 siRNA (20 pmol) treatment resulted in a 2Á8-fold increase (P < 0Á05); 5Á5-fold increase (P < 0Á01); 3Á0-fold increase (P < 0Á05); and 13Á5-fold increase (P < 0Á0001) in the gene expression levels of IL-17A, IL-17B, IL-17C and IL-17E (Fig. 6) , respectively. Treatment with Gal-3 inhibitor peptide (10 nmol) resulted in a 2Á8-fold increase (P < 0Á05); 12Á7-fold increase (P < 0Á0001); 3Á5-fold increase (P < 0Á05); and 11Á7-fold increase (P < 0Á0001) in the gene expression levels of IL-17A, IL-17B, IL-17C and IL-17E, respectively (Fig. 5) . Both Gal-3 siRNA silencing and Gal-3 inhibition with Ac-SDKP resulted in a decrease in IL-17D gene expression but the effect was not statistically significant. These data suggest that Gal-3 may play a pivotal role in the balance between a pro-inflammatory response and a protective anti-inflammatory response by modulation of IL-17 levels that either exacerbate or attenuate the allergic response in asthma.
Discussion
Asthma appears to be due to allergic and non-allergic mechanisms, with allergic asthma associated with Th2-associated elements, and non-allergic asthma associated with non-Th2-associated elements, such as Th1, Th17 and neutrophilic inflammation. 30 With 50% of asthma linked to non-Th2 mechanisms, that are associated with variable response to corticosteroid therapy, intricate integration of animal and human studies is urgently needed to delineate the molecular phenotypes of this asthma type. 6 One non-Th2-mediated endotype of asthma associated with steroid resistance is a subtype with high IL-17 and high IFN-c levels, which may be possible therapeutic targets. 31 Another study by McKinley et al., 32 also notes Th17 cells linked to steroid resistance in a murine model of asthma. Investigators examining expression of IL-17A and IL-17F in the airways of asthmatic patients detected increased IL-17A and IL-17F immunoreactivity in lung tissue sections obtained via bronchoscopy, and measured L-17A and IL-17F cytokine mRNA expression that increased with asthma severity. 33 The airway smooth muscle hypertrophy associated with asthma may interact with components of the ECM, the enzymes that degrade the ECM, MMP and the inhibitors of MMP enzymes, TIMP. 34 Similar to the observations of our TIMP-1 KO study on murine asthma, Gal-3 is associated with ECM turnover and is also reported to be involved in many aspects in asthma, such as eosinophil recruitment airway remodelling, development of a Th2 phenotype as well as increased expression of inflammatory mediators. 11, 35, 36 The imbalance between MMPs (particularly MMP-2 and MMP-9) and TIMPs (particularly TIMP-1) plays an active role in airway remodelling in asthma, with the MMP-9/TIMP-1 ratio elevated in individuals with asthma compared with non-asthmatic control participants. Gene expression levels of IL-17 subtypes A-E in A549 cells treated with Gal-3 small interfering RNA (siRNA) and Gal-3 inhibitor (Ac-SDKP). Data are presented as mean AE SD from n = 3 separate experiments. *P < 0.05, **P < 0.01, ***P < 0.0001.
In a previous study, Sands et al. employed TIMP-1 KO mice to assess the allergic response of a murine model of OVA-induced allergic asthma, which suggests that TIMP-1 plays a protective role by preventing airway hyperreactivity and modulating inflammation, remodelling and cytokine expression in this animal model of asthma. 15 Galectins are b-galactoside binding lectins that regulate biological and cellular processes such as production of inflammatory mediators, cell adhesion, migration and apoptosis. 41, 42 Galectins are expressed by various cell types, specifically eosinophils, which are present in large numbers in the lungs and airways in allergic asthma. Various members of the Galectin family differentially regulate eosinophil recruitment, activation and apoptosis and therefore exert a pro-or anti-inflammatory outcome.
To determine the impact that MMP-2 and MMP-9 may have on Gal-3 and components of the ECM, we examined the expression of Gal-3 in the TIMP1 KO mice exposed to OVA challenges compared with WT controls. MMP-2 and MMP-9 efficiently cleave Gal-3 into two fragments, allowing the carbohydrate domain to bind to glycosylated ligands with higher affinity, but abolish the ability of the molecules to self-associate and develop homodimers. 16, 17 Given that TIMP-1 KO mice had increased levels of MMP-2 and MMP-9, we expected less intact Gal-3 leading to a reduced Th2 response. Acute allergen exposure is believed to result in increased recruitment of Gal-3-expressing inflammatory cells such as macrophages and eosinophils to the airways resulting in elevated levels of Gal-3 in the lung.
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A comparative analysis of the gene expression levels of key Galectins and cytokines in lung tissue, between OVAsensitized TIMP-1 KO and WT SHAM controls showed a significant increase in Gal-3, TGF-b 1 and IL-17 expression in OVA-sensitized TIMP-1 KO mice (Fig. 1a) . Similar gene expression trends were observed when gene expression levels of Gal-1, Gal-3, Gal-9, TGF-b 1 , TGF-b 3 , IL-1b, IFN-c and IL-17 were compared in OVA-sensitized TIMP-1 KO and OVA-sensitized WT mice (Fig. 1b) . However significantly higher TGF-b 1 gene expression levels were observed in OVA-sensitized TIMP-1 KO mice when compared with the OVA-sensitized WT mice (Fig. 1b) . TGF-b 1 is believed to be a neutrophil chemoattractant and may promote Th17 differentiation, 33 so increased expression of TGF-b 1 may also contribute the increased IL-17 gene expression in these OVA-sensitized mice.
We evaluated the gene and protein expression levels of Gal-3 in lung tissue as well as soluble Gal-3 levels in serum obtained from OVA-sensitized TIMP-1 KO and WT mice and compared the levels to those obtained from WT SHAM and TIMP-1 KO SHAM mice. Our data showed a significant increase in Gal-3 expression in OVA-sensitized animals from both the WT and TIMP-1 KO groups compared with the SHAM controls, corroborating reports from previous studies suggesting that Gal-3 plays a pro-inflammatory role in allergic asthma by promoting eosinophil trafficking and migration. In contrast to its pro-inflammatory role in allergic asthma, some studies have shown that Gal-3 can suppress eosinophil infiltration and normalize pulmonary function in acute as well as chronic settings of allergic asthma by negatively regulating gene expression of suppressors of cytokine signalling, which play an important role in controlling the Th1-Th2 balance. [43] [44] [45] In the context of asthma, several studies have highlighted the role of Gal-3 as a key mediator of the Th1-Th2 balance. In a murine model of OVA-induced asthma phenotype, Gal-3 was expressed by airway immune cells, particularly macrophages in bronchoalveolar lavage fluid (BALF), with increased Gal-3 expressed in the BALF of OVA-challenged mice compared with the control mice.
In Gal-3 KO mice (gal3 À/À ) compared with WT mice there were fewer eosinophils; there was lower goblet cell metaplasia and Th2 response but a higher Th1 response after OVA challenge. 11 Examination of the bronchial epithelium samples noted increased Gal-3, and neutrophils in the small airways of individuals of chronic obstructive pulmonary disease (COPD) compared with individuals without COPD who smoke. 46 In gal3 À/À mice challenged with chronic OVA exposure of 12 weeks, examination of the lung tissue and BALF reveals decreased airway remodelling, decreased subepithelial fibrosis, decreased airway smooth muscle thickness, and decreased peribronchial angiogenesis, compared with wild-type mice chronically exposed to OVA. 35 
Gal3
À/À mice chronically exposed to OVA also had lower levels of IL-5, IL-13 and TGF-b compared with WT mice with chronic OVA exposure. 35 In a mouse model of pulmonary infection with inhaled Francisella novicida, WT mice had increased Gal-3 expression and extracellular release after pulmonary infection, as opposed to gal3 À/À mice with reduced inflammatory response (tumour necrosis factor-a, IL-10, IL-1b), decreased neutrophil activity in the lung tissue, and improved survival. 47 Further, Gal-3 was decreased in BALF from individuals with COPD compared with smokers without COPD and non-smoking controls, and addition of exogenous Gal-3 to human alveolar macrophages obtained from BALF led to increased efferocytosis. 48 These studies in Gal-3-deficient mice and data from the current study suggest a putative role for Gal-3 in modulating allergic asthma.
We observed a significant increase in IL-8 and a decrease in MCP-1 gene expression levels in A549 cells treated with Gal-3 inhibitor (Fig. 5) , suggesting that Gal-3 may regulate the balance between pro-inflammatory and anti-inflammatory responses that modulates the progression of allergic asthma. Further, we observed that Gal-3 silencing resulted in a significant increase in IL-17A, -B, -C and E gene expression levels (Fig. 6 ) in A549 lung epithelial cells, indicating that Gal-3 is a key mediator of inflammation and exerts its effects through the modulation of other cytokine/chemokine regulators such as TGF-b. Interleukin-17 induces MMPs, which aids collagen destruction, and neutrophil recruitment could further sustain pro-inflammatory responses that might be particularly damaging in asthma. Th17 cell differentiation, characterized by IL-17 production, depends on the presence of TGF-b and IL-6. The presence of TGF-b drives Th17 cell differentiation and down-regulates Th1 cell differentiation through the inhibition of IFN-c, whereas IL-12 inhibits the development of Th17 cells. Traditionally, TGF-b is an anti-inflammatory cytokine, a paradox given its role as a crucial factor for the differentiation of the IL-17-producing T-cell subset Th17. This highlights the fact that it is a cytokine with numerous functions and that TGF-b regulates a plethora of biological processes including inflammation and tissue repair. Studies showed that IL-17 monoclonal antibody was moderately effective only with individuals with good responses to bronchodilator use, suggesting that IL-17 contributes to less severe disease. [49] [50] [51] Pro-inflammatory cytokines such as IL-17 are also potent inducers of MUC5B and also regulate the expression of Gal-3 in allergic asthma, as observed in our study. It is speculated, that protein-protein interactions between MUC5B and Gal-3 could alter the biophysical properties of mucus -Gal-3 via carbohydrate-dependent interactions with cell-surface mucins maintaining mucosal barrier function in the eye. 52 Mucin-Gal-3 interactions may contribute substantially to the integrity of mucosal epithelial barrier function and may regulate the transcellular flux of extracellular components into epithelial cells. 53, 54 Additional studies to evaluate associations between Gal-3 and the Mucin family and their role in allergic asthma need to be investigated.
In summary, our study suggests that Gal-3 may be a key regulator of the fine balance between pro-inflammatory and anti-inflammatory responses in the progression of allergic asthma. These studies have enormous clinical translational significance, as administration of exogenous Gal-3 could potentially serve as a therapeutic tool for allergic asthma. Increased Gal-3 levels in the bronchial tissues, derived from asthmatic individuals who are refractory to corticosteroid therapy, can predict the response or non-response of the patient to the treatment regimen before treatment with the anti-IgE multiclonal antibody, omalizumab,. 55 The authors posit that the rationale for this action is the ability of Gal-3 to disrupt IgE and FceR1 interactions, improving anti-IgE efficacy.
Conclusion
Our results showed a significant increase in Gal-3 gene and protein expression in OVA-treated TIMP-1 KO mice compared with the WT controls, which is associated with increased expression of inflammatory mediators such as IL-17 that further contribute to asthma progression. This study confirms that Gal-3 plays a significant role in the pathophysiological mechanisms in asthma and may be a candidate biomarker or therapeutic target for specific asthma endotypes.
